Compare CMPR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | AGIO |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | CMPR | AGIO |
|---|---|---|
| Price | $70.95 | $24.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $80.50 | $32.13 |
| AVG Volume (30 Days) | 190.6K | ★ 1.6M |
| Earning Date | 01-28-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $3,461,387,000.00 | $44,791,000.00 |
| Revenue This Year | $8.23 | $28.75 |
| Revenue Next Year | $4.83 | $139.45 |
| P/E Ratio | $52.61 | ★ N/A |
| Revenue Growth | 3.65 | ★ 36.26 |
| 52 Week Low | $35.21 | $22.24 |
| 52 Week High | $76.65 | $46.00 |
| Indicator | CMPR | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 31.88 |
| Support Level | $73.60 | $24.16 |
| Resistance Level | $76.60 | $27.95 |
| Average True Range (ATR) | 2.50 | 1.03 |
| MACD | -0.38 | 0.21 |
| Stochastic Oscillator | 18.06 | 12.60 |
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.